by
Lisa Chamoff, Contributing Reporter | June 05, 2017
From the June 2017 issue of HealthCare Business News magazine
“In a dual-headed system, the sensitivity is lower because the surface of the crystal is less,” Nemeth says. “Three heads provide better coverage of the body in a single shot.”
With the AnyScan TRIO, Mediso is the first SPECT manufacturer to release a clinical system with multiple pinhole aperture technology, which provides much higher spatial resolution and sensitivity.
Ad Statistics
Times Displayed: 109208
Times Visited: 6638 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“It brings the benefits of preclinical imaging technology, which has extremely high resolution and sensitivity, to the clinical imaging space,” says Jeff Sumeracki, regional sales manager for Absolute Imaging Solutions, Mediso’s U.S. distributor. “This technology brings near-PET-quality imaging to the SPECT world.”
Last year, the company installed the first AnyScan TRIO systems in Europe. Absolute Imaging Solutions intends to assist with installation and delivery of the first TRIO systems in the U.S. in conjunction with the application for FDA 510(k) clearance.
Philips
Philips introduced its Vereos digital PET/CT in 2013. Kirill Shalyaev, vice president and general manager for advanced molecular imaging at Philips, says the system provides twice the volumetric resolution, improvement of sensitivity gain and quantitative accuracy, leading to smaller lesion detectability and a lower radiation dose.
At this year’s SNMMI annual meeting, the company plans to present a number of abstracts showing early indications of the system’s clinical benefits.
Shalyaev says he has seen the overall PET/CT market expand by double digits in the last two years, calling PET/CT the “fastest-growing imaging modality” due to continued adoption and the emergence of new radiopharmaceuticals, including agents for oncology as well as amyloid imaging.
While FDG PET is the gold standard for cancer staging, Shalyaev points to growing applications for early therapy planning and response assessment.
“Oncology, in particular, is a big area of growth,” Shalyaev says. “Dementia and neuro is a new frontier.”
